Gloria Biosciences

Focus: Gloria Biosciences is a monoclonal antibody-focused biotech company headquartered in Guangzhou, China, operating across oncology, neurology, nephrology, hematology, and respiratory indications. The company is early-stage with a pipeline of 11 active clinical programs spanning Phase 1 through Phase 3.

Oncology Neurology Nephrology Hematology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Gloria Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Gloria Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

evidence-based online feedback

Respiratory Infections

N/A

Clinical Trials (1)

NCT02927743Effect of Evidence-based Reminders on Use of Antibiotics

N/A

Help build intelligence for Gloria Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active Phase 3 pipeline with 3 programs in advanced development, including GLS-010 in Hodgkin's Lymphoma and cervical cancer with near-term regulatory catalysts
Focused mAb platform across high-unmet-need oncology indications (Hodgkin's, cervical cancer, NSCLC, multiple myeloma) offering deep disease expertise
Geographic arbitrage opportunity in China biotech with multi-indication oncology portfolio positioning for emerging market expansion

Watch Out For

Zero open job positions at time of data capture signals potential hiring freeze or organizational uncertainty
Substantial pipeline data quality issues (non-pharma modalities like 'cow's milk kefir' and cognitive training listed) suggest database management or operational maturity concerns
Missing critical transparency data (founding year, employee count, funding, financial performance) limits ability to assess company stability and growth trajectory

Generated by Claude from Gloria Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Computerised cognitive training

Huntington's Disease

N/A

Clinical Trials (1)

NCT02990676Exploring Computerised Cognitive Training for People With Huntington's Disease

N/A

cow's milk kefir

Iron Deficiency Anemia

N/A

Clinical Trials (1)

NCT06957717Effect of Cow's Milk Kefir on Short Chain Fatty Acid (SCFA), Haemoglobin, and Ferritin Levels of Anemic Adolescent Girls

N/A

Eldecalcitol

Osteoporosis

N/A

Clinical Trials (1)

NCT01974167Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

N/A

C-mill intervention

Hereditary Spastic Paraplegia

N/A

Clinical Trials (1)

NCT04180098Improving Gait Adaptability in Hereditary Spastic Paraplegia

N/A

Finger Force Manipulandum

Dystonic Disorders

N/A

Clinical Trials (1)

NCT02882334Finger Individuation Training With a Training Device Versus Conventional Rehabilitation for Writer's Cramp

N/A

MIT-ED

Eating Disorders

N/A

Clinical Trials (1)

NCT06693089Metacognitive Interpersonal Therapy Across Transdiagnostic Eating Disorders, Including Underweight

N/A

ROG

Bone Regeneration

N/A

Clinical Trials (1)

NCT03785717Horizontal Ridge Augmentation in Mandible Usign ROG + ESWT

N/A

GLS-010

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT03713905Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Phase 1

GLS-012+GLS-010

Advanced Non-Small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT05978401Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2

GLS-012

Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05909436Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Phase 1/2

GLS-010

Classical Hodgkin's Lymphoma

Phase 2

Clinical Trials (1)

NCT03655483Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Phase 2

GLS-010

Cervical Cancer

Phase 2

Clinical Trials (1)

NCT03972722Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2

Zimberelimab 240mg

Classical Hodgkin Lymphoma

Phase 2

Clinical Trials (1)

NCT05900765A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Phase 2

Alirocumab

Nephrotic Syndrome

Phase 2

GLS-010

Classic Hodgkin's Lymphoma

Phase 3

Clinical Trials (1)

NCT05518318GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Phase 3

Motixafortide+G-CSF

Multiple Myeloma

Phase 3

Clinical Trials (1)

NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Phase 3

GLS-010

Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3

Clinical Trials (1)

NCT05798819A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3